Skip to Main Content
Try STAT+ TODAY
Trending:
Pharmalot
Coronavirus
Biotech
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

Not-so-happy midyear! Biotech CEOs, best and worst, and a hopeful sign of a turnaround

  • Adam Feuerstein

By Adam Feuerstein July 1, 2022

Reprints
Adam's take main illustration
Molly Ferguson/STAT

A few things on my mind:

A very strange — and painful — year in biotech calls for an unusual nominee to occupy a spot on my annual list of the best CEOs, which is why I’m looking at Catalyst Biosciences’ Nassim Usman.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Create a display name to comment

This name will appear with your comment

Your questions on the new Covid vaccine boosters answered
Your questions on the new Covid vaccine boosters answered
A Q&A with WHO’s Maria Van Kerkhove on Covid…
A Q&A with WHO’s Maria Van Kerkhove on Covid — and fatigue over the pandemic
U.S. life expectancy drops sharply, the second consecutive decline
U.S. life expectancy drops sharply, the second consecutive decline
Pharmalittle: Illumina faces more challenges after winning FTC case;…
Pharmalittle: Illumina faces more challenges after winning FTC case; Novo Nordisk buys Forma Therapeutics
Illumina wins case against FTC in bid to hold…
Illumina wins case against FTC in bid to hold onto early cancer detection company Grail
Listen: The anti-aging research boom, the Godfather of biotech,…
Listen: The anti-aging research boom, the Godfather of biotech, & the future of Biogen

Recommended Stories